Human blood groups: Incidental receptors for viruses and bacteria

Transfusion

Volumn 36, Issue 4, 1996, Pages 362-374

  Moulds, J M ^a   Nowicki, S ^b   Moulds, J J ^c   Nowicki, B J ^b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c Gamma Biologicals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD GROUP ANTIGEN; GLYCOLIPID; GLYCOPROTEIN; VIRUS RECEPTOR;

AGGLUTINATION TEST; ANTIGEN SPECIFICITY; BACTERIUM ISOLATION; BLOOD GROUP; BLOOD GROUP LEWIS SYSTEM; BLOOD GROUP P SYSTEM; BLOOD TRANSFUSION; HUMAN; MOLECULAR RECOGNITION; NULL CELL; REVIEW;

EID: 0029962398     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.1996.36496226154.x     Document Type: Review

References (126)

1. Duguid JP, Gillies RR. Fimbriae and adhesive properties in dysentery bacilli. J Pathol Bacteriol 1957;74:397-11.
2. Duguid JP, Smith IW, Dempster G, Edmunds PN. Non-flagellar filamentous appendages ("fimbriae") and haemagglutinating activity in Bacterium coli. J Pathol Bacteriol 1955;70:335-48.
3. Brinton CC. Non-flagellar appendages of bacteria. Nature 1959;183:782-6.
4. Korhonen TK. Yeast cell agglutination by purified enterobacterial pili. FEMS Microbiol Lett 1979;6:421-5.
5. Korhonen TK, Leffler H, Svanborg-Edén C. Binding specificity of piliated strains of Escherichia coli and Salmonella typhimurium to epithelial cells, saccharomyces cerevisiae cells, and erythrocytes. Infect Immun 1981;32:796-804.
6. Edén CS, Hansson HA. Escherichia coli pili as possible mediators of attachment to human urinary tract epithelial cells. Infect Immun 1978;21:229-37.
7. Svanborg-Edén C, Jodal U. Attachment of Escherichia coli to urinary sediment epithelial cells from urinary tract infection-prone and healthy children. Infect Immun 1979;26:837-40.
8. Edén CS, Larsson P, Lomberg H. Attachment of Proteus mirabilis to human urinary sediment epithelial cells in vitro is different from that of Escherichia coli. Infect Immun 1980;27:804-7.
9. Kallenius G, Mollby R, Svenson SB, et al. Identification of a carbohydrate receptor recognized by uropathogenic Escherichia coli. Infection 1980;8(Suppl 3):288-93.
10. K antigen as receptor for the haemagglutinin of pyelonephritic Escherichia coli. FEMS Microbiol Lett 1980;7:297-302.
11. Leffler H, Svanborg-Edén C. Chemical identification of a glycosphingolipid receptor for Escherichia coli attaching to human urinary tract epithelial cells and agglutinating human erythrocytes. FEMS Microbiol Lett 1980;8:127-34.
12. Moulds JM. Association of blood group antigens with immunologically important proteins. In: Garratty G, ed. Immunobiology of transfusion medicine. New York: Marcel Dekker, 1994:273-97.
13. Pittiglio DH. Genetics and biochemistry of A,B,H and Lewis antigens. In: Wallace ME, Gibbs FL, eds. Blood group systems: ABH and Lewis. Arlington: American Association of Blood Banks, 1986:1-56.
14. Greenwell P, Johnson PH, Edwards JM, et al. Association of the human Lewis blood group Le(a-b-c-d-) with the failure of expression of alpha-3-L-fucosyltransferase. Rev Fr Transfus Immunohematol 1986;29:233-49.
15. Jantausch BA, Criss VR, O'Donnell R, et al. Association of Lewis blood group phenotypes with urinary tract infection in children. J Pediatr 1994;124:863-8.
16. Essery SD, Saadi AT, Twite SJ, et al. Lewis antigen expression on human monocytes and binding of pyrogenic toxins. Agents Actions 1994;41:108-10.
17. Graham DY. Evolution of concepts regarding Helicobacter pylori: from a cause of gastritis to a public health problem (editorial). Am J Gastroenterol 1994;89:469-72.
18. Boren T, Falk P, Roth KA, et al. Attachment of Helicobacter pylori to human gastric epithelium mediated by blood group antigens. Science 1993;262:1892-5.
19. Azuma T, Konishi J, Tanaka Y, et al. Contribution of HLA-DQA gene to host's response against Helicobacter pylori (letter). Lancet 1994;343:542-3.
20. Ruiz B, Correa P, Fontham ET, et al. Ascorbic acid, Helicobacter pylori and Lewis phenotype among blacks and whites in New Orleans. Cancer Lett 1994;83:323-9.
21. a and Pr. Arlington: American Association of Blood Banks, 1991:1-22.
22. Brown KE, Anderson SM, Young NS. Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science 1993;262:114-7.
23. Brown KE, Hibbs JR, Gallinella G, et al. Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen). N Engl J Med 1994;330:1192-6.
24. Gilboa-Garber N, Sudakevitz D, Sheffi M, et al. PA-I and PA-II lectin interactions with the ABO(H) and P blood group glycosphingolipid antigens may contribute to the broad spectrum adherence of Pseudomonas aeruginosa to human tissues in secondary infections. Glycoconj J 1994;11:414-7.
25. Kallenius G, Svenson S, Mollby R, et al. Structure of carbohydrate part of receptor on human uroepithelial cells for pyelonephritogenic Escherichia coli. Lancet 1981;2:604-6.
26. Kallenius G, Svenson SB, Mollby R, et al. Carbohydrate receptor structures recognized by uropathogenic E. coli. Scand J Infect Dis Suppl 1982;33:52-60.
27. Svanborg Eden C, de Man P. Bacterial virulence in urinary tract infection. Infect Dis Clin North Am 1987;1:731-50.
28. Svenson SB, Hultberg H, Kallenius G, et al. P-fimbriae of pyelonephritogenic Escherichia coli: identification and chemical characterization of receptors. Infection 1983;11:61-7.
29. Bock K, Breimer ME, Brignole A, et al. Specificity of binding of a strain of uropathogenic Escherichia coli to Galαl-4Gal-containing glycosphingolipids. J Biol Chem 1985;260:8545-51.
30. De Man P, Cedergren B, Enerback S, et al. Receptor-specific agglutination tests for detection of bacteria that bind globoseries glycolipids. J Clin Microbiol 1987;25:401-6.
31. Leffler H, Svanborg-Edén C. Glycolipid receptors for uropathogenic Escherichia coli on human erythrocytes and uroepithelial cells. Infect Immun 1981;34:920-9.
32. Senior D, Baker N, Cedergreen B, et al. Globo-A - a new receptor specificity for attaching Escherichia coli. FEBS Lett 1988;237:123-7.
33. Salit IE, Vavougios J, Hofmann T. Isolation and characterization of Escherichia coli pili from diverse clinical sources. Infect Immun 1983;42:755-62.
34. Lindstedt R, Baker N, Falk P, et al. Binding specificities of wild-type and cloned Escherichia coli strains that recognize globo-A. Infect Immun 1989;57:3389-94.
35. Karr JF, Nowicki B, Truong LD, et al. Purified P fimbriae from two cloned gene clusters of a single pyelonephritogenic strain adhere to unique structures in the human kidney. Infect Immun 1989;57:3594-600.
36. Van Die I, Spierings G, Van Megan I, et al. Cloning and genetic organization of the gene cluster encoding F71 fimbriae of a uropathogenic Escherichia coli and comparison with the F72 gene cluster. FEMS Microbiol Lett 1985;28:329-34.
37. Tippett P, Andrews PW, Knowles BB, et al. Red cell antigens P (globoside) and Luke: identification by monoclonal antibodies defining the murine stage-specific embryonic antigens -3 and -4 (SSEA-3 and SSEA-4). Vox Sang 1986;51:53-6.
38. Breimer ME. Chemical and immunological identification of the Forssman pentaglycosylceramide in human kidney. Glycoconjugate J 1985;2:375-85.
39. Korhonen TK, Nowicki B, Rhen M, et al. Fimbrial phase variation in Escherichia coli: a mechanism of bacterial virulence? In: Lark DL. Protein-carbohydrate interactions in biological systems. London: Academic Press, 1986:245-51.
40. Hull S, Clegg S, Sanborg-Eden C, Hull R. Multiple forms of genes in pyelonephritogenic Escherichia coli encoding adhesins binding globoseries glycolipid receptors. Infect Immun 1985;47:80-3.
41. Karr JF, Nowicki BJ, Truong LD, et al. pap-2-encoded fimbriae adhere to the P blood group-related glycosphingolipid stage-specific embryonic antigen 4 in the human kidney. Infect Immun 1990;58:4055-62.
42. Korhonen TK, Virkola R, Holthofer H. Localization of binding sites for purified Escherichia coli P fimbriae in the human kidney. Infect Immun 1986;54:328-32.
43. Siegel DL, Silberstein LE. Red cell antigen specificities and autoimmune hemolytic anemias. In: Agre P, Cartron JP, eds. Protein blood group antigens of the human red cell: structure, function, and clinical significance. Baltimore: Johns Hopkins Univ Press, 1992:193-208.
44. Hakomori S. Blood group ABH and Ii antigens of human erythrocytes: chemistry, polymorphism, and their developmental change. Semin Hematol 1981;18:39-62.
45. Thomas ML. The leukocyte common antigen family. Annu Rev Immunol 1989;7:339-69.
46. Barile MF, Chandler DK, Yoshida H, et al. Parameters of Mycoplasma pneumoniae infection in Syrian hamsters. Infect Immun 1988;56:2443-9.
47. Layh-Schmitt G. The ORF6 gene product of the P1 operon of Mycoplasma pneumoniae. Int J Med Microbiol Parasitol Infect Dis 1993;278:287-95.
48. Loomes LM, Uemura K, Childs RA, et al. Erythrocyte receptors for Mycoplasma pneumoniae are sialylated oligosaccharides of Ii antigen type. Nature 1984;307:560-3.
49. Parsons SF, Spring FA, Merry AH. Evidence that Cromer-related blood group antigens are carried on decay accelerating factor (DAF) suggests that the Inab phenotype is a novel form of DAF deficiency (abstract). Presented at the 20th Congress of the International Society of Blood Transfusion, London, UK, July 1988:116.
50. Telen MJ, Hall SE, Green AM, et al. Identification of human erythrocyte blood group antigens on decay-accelerating factor (DAF) and an erythrocyte phenotype negative for DAF. J Exp Med 1988;167:1993-8.
51. Nowicki B, Hull R, Moulds J. Use of the Dr hemagglutinin of uropathogenic Escherichia coli to differentiate normal from abnormal red cells in paroxysmal nocturnal hemoglobinuria (letter). N Engl J Med 1988;319:1289-90.
52. Rey-Campos J, Rubinstein P, Rodriguez de Cordoba S. Decay-accelerating factor. Genetic polymorphism and linkage to the RCA (regulator of complement activation) gene cluster in humans. J Exp Med 1987;166:246-52.
53. Medof ME, Walter EI, Roberts WL, et al. Decay accelerating factor of complement is anchored to cells by a C-terminal glycolipid. Biochemistry 1986;25:6740-7.
54. Lublin DM, Coyne KE. Phospholipid-anchored and transmembrane versions of either decay-accelerating factor or membrane cofactor protein show equal efficiency in protection from complement-mediated cell damage. J Exp Med 1991;174:35-44.
55. Pangburn MK, Schreiber RD, Muller-Eberhard HJ. Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci U S A 1983;80:5430-47.
56. Nicholson-Weller A, March JP, Rosenfeld SI, Austen KF. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor. Proc Natl Acad Sci U S A 1983;80:5066-70.
57. Medof ME, Kinoshita T, Silber R, Nussenzweig V. Amelioration of lytic abnormalities of paroxysmal nocturnal hemoglobinuria with decay-accelerating factor. Proc Natl Acad Sci U S A 1985;82:2980-4.
58. Stafford HA, Tykocinski ML, Lublin DM, et al. Normal polymorphic variations and transcription of the decay-accelerating factor gene in paroxysmal nocturnal hemoglobinuria cells. Proc Natl Acad Sci U S A 1988;85:880-4.
59. a. Transfusion 1984;24:13-5.
60. a and a family with the Dr(a-) phenotype in two generations. Transfusion 1987;27:64-5.
61. Ahearn JM, Fearon DT. Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21). Adv Immunol 1989;46:183-219.
62. Pham T, Kaul A, Hart A, et al. dra-related X adhesins of gestational pyelonephritis-associated Escherichia coli recognize SCR-3 and SCR-4 domains of recombinant decay-accelerating factor. Infect Immun 1995;65:1663-8.
63. Vaisanen-Rhen V. Fimbria-like hemagglutinin of Escherichia coli O75 strains. Infect Immun 1984;46:401-7.
64. Labigne-Roussel A, Falkow S. Distribution and degree of heterogeneity of the afimbrial-adhesin-encoding operon (afa) among uropathogenic Escherichia coli isolates. Infect Immun 1988;56:640-8.
65. Labigne-Roussel AF, Lark D, Schoolnik G, Falkow S. Cloning and expression of an afimbrial adhesin (AFA-I) responsible for P blood group-independent, mannose-resistant hemagglutination from a pyelonephritic Escherichia coli strain. Infect Immun 1984;46:251-9.
66. Arthur M, Johnson CE, Rubin RH, et al. Molecular epidemiology of adhesin and hemolysin virulence factors among uropathogenic Escherichia coli. Infect Immun 1989;57:303-13.
67. Nowicki B, Svanborg-Eden C, Hull R, Hull S. Molecular analysis and epidemiology of the Dr hemagglutinin of uropathogenic Escherichia coli. Infect Immun 1989;57:446-51.
68. Nowicki B, Moulds J, Hull R, Hull S. A hemagglutinin of uropathogenic Escherichia coli recognizes the Dr blood group antigen. Infect Immun 1988;56:1057-60.
69. Daniels GL, Tohyama H, Uchikawa M. A possible null phenotype in the Cromer blood group complex. Transfusion 1982;22:362-3.
70. Nowicki B, Labigne A, Moseley S, et al. The Dr hemagglutinin, afimbrial adhesins AFA-I and AFA-III, and F1845 fimbriae of uropathogenic and diarrhea-associated Escherichia coli belong to a family of hemagglutinins with Dr receptor recognition. Infect Immun 1990;58:279-81.
71. Nowicki B, Truong L, Moulds J, Hull R. Presence of the Dr receptor in normal human tissues and its possible role in the pathogenesis of ascending urinary tract infection. Am J Pathol 1988;133:1-4.
72. Kaul A, Nowicki BJ, Martens MG, et al. Decay-accelerating factor is expressed in the human endometrium and may serve as the attachment ligand for Dr pili of Escherichia coli. Am J Reprod Immunol 1994;32:194-9.
73. Kornonen TK, Virkola R, Vaisasen-Rhen V, Holthofer H. Binding of purified Escherichia coli O75X adhesin to frozen sections of human kidney. FEMS Microbiol Lett 1994;32:194-9.
74. Fowler JE Jr, Stamey TA. Studies of introital colonization in women with recurrent urinary infections. VII. The role of bacterial adherence. J Urol 1977;117:472-6.
75. Nowicki B, Barrish JP, Korhonen T, et al. Molecular cloning of the Escherichia coli O75X adhesin. Infect Immun 1987;55:3168-73.
76. Westerlund B, Kuusela P, Risteli J, et al. The O75X adhesin of uropathogenic Escherichia coli is a type IV collagen-binding protein. Mol Microbiol 1989;3:329-37.
77. Nowicki B, Hart A, Coyne KE, et al. Short consensus repeat-3 domain of recombinant decay-accelerating factor is recognized by Escherichia coli recombinant Dr adhesin in a model of a cell-cell interaction. J Exp Med 1993;178:2115-21.
78. Kaul A, Nagamam M, Nowicki B. Decreased expression of endometrial decay accelerating factor (DAF), a complement regulatory protein, in patients with luteal phase defect. Am J Reprod Immunol 1995;34:236-40.
79. Bergelson JM, Chan M, Soloman KR, et al. Decay-accelerating factor (CD55), a glycosylphosphatidylinositol-anchored complement regulatory protein, is a receptor for several echoviruses. Proc Natl Acad Sci U S A 1994;91:6245-9.
80. Clarkson NA, Kaufman R, Lublin DM. et al. Characterization of the echovirus 7 receptor: domains of CD55 critical for virus binding. J Virol 1995;69:5497-501.
81. Lublin DM, Thompson ES, Green AM, et al. Dr(a-) polymorphism of decay accelerating factor. Biochemical, functional, and molecular characterization and production of allele-specific transfectants. J Clin Invest 1991;87:1945-52.
82. Moulds JM, Nickells MW, Moulds JJ, et al. The C3b/C4b receptor is recognized by the Knops, McCoy, Swain-langley, and York blood group antisera. J Exp Med 1991;173:1159-63.
83. Rao N, Ferguson DJ, Lee SF, Telen MJ. Identification of human erythrocyte blood group antigens on the C3b/C4b receptor. J Immunol 1991;146:3502-7.
84. Fearon DT. Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte polymorphonuclear leukocyte. B lymphocyte, and monocyte. J Exp Med 1980;152:20-30.
85. Wong WW, Wilson JG, Fearon DT. Genetic regulation of a structural polymorphism of human C3b receptor. J Clin Invest 1983;72:685-93.
86. Dykman TR, Cole JL, Iida K, Atkinson JP. Polymorphism of human erythrocyte C3b/C4b receptor. Proc Natl Acad Sci USA 1983;80:1698-702.
87. Dykman TR, Hatch JA, Atkinson JP. Polymorphism of the human C3b/C4b receptor. Identification of a third allele and analysis of receptor phenotypes in families and patients with systemic lupus erythematosus. J Exp Med 1984;159:691-703.
88. Dykman TR, Hatch JA, Aqua MS, Atkinson JP. Polymorphism of the C3b/C4b receptor (CR1): characterization of a fourth allele. J Immunol 1985;134:1787-9.
89. Wilson JG, Murphy EE, Wong WW, et al. Identification of a restriction fragment length polymorphism by a CR1 cDNA that correlates with the number of CR1 on erythrocytes. J Exp Med 1986;164:50-9.
90. Wong WW, Kennedy CA, Bonaccio ET, et al. Analysis of multiple restriction fragment length polymorphisms of the gene for the human complement receptor type 1. Duplication of genomic sequences occurs in association with a high molecular mass receptor allotype. J Exp Med 1986;164:1531-46.
91. Cohen JH, Autran B, Jouvin MH, et al. [Decrease of erythrocyte receptors for the C3b fragment of complement in acquired immunodeficiency syndrome] (Engl abstract). Presse Med 1988;17:727-30.
92. Tausk FA, McCutchan JA, Spechko P, et al. Altered erythrocyte C3b receptor expression, immune complexes, and complement activation in homosexual men in varying risk groups for acquired deficiency syndrome. J Clin Invest 1986;78:977-82.
93. Iida K, Mornaghi R, Nussenzweig V. Complement receptor (CR1) deficiency in erythrocytes from patients with systemic lupus erythematosus. J Exp Med 1982;155:1427-38.
94. Moulds JM, Brown LL. Loss of complement receptor one (CR1) from stored blood and its effect on Knops blood group reactivity. Immunohematology 1995;11:46-50.
95. Ebenbichler CF, Thielens NM, Vornhagen R, et al. Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41. J Exp Med 1991;174:1417-24.
96. Thielens NM, Bally IM, Ebenbichler CF, et al. Further characterization of the interaction between the C1q subcomponent of human C1 and the transmembrane envelope glycoprotein gp41 of HIV-1. J Immunol 1993;151:6583-92.
97. Banapour B, Sernatinger J, Levy JA. The AIDS-associated retrovirus is not sensitive to lysis or inactivation by human serum. Virology 1986;152:268-71.
98. Marschang P, Sodroski J, Wurzner R, Dierich MP. Decay-accelerating factor (CD55) protects human immunodeficiency virus type 1 from inactivation by human complement. Eur J Immunol 1995;25:285-90.
99. Saifuddin M, Parker CJ, Peeples ME, et al. Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. J Exp Med 1995;182:501-9.
100. Delibrias CC, Mouhoub A, Fischer E, Kazatchkine MD. CR1 (CD35) and CR2 (CD21) complement C3 receptors are expressed on normal human thymocytes and mediate infection of thymocytes with opsonized human immunodeficiency virus. Eur J Immunol 1994;24:2784-8.
101. Delibrias CC, Kazatchkine MD, Fischer E. Evidence for the role of CR1 (CD35), in addition to CR2 (CD21), in facilitating infection of human T cells with opsonized HIV. Scand J Immunol 1993;38:183-9.
102. Montefiori DC, Graham BS, Zhou JY, et al. Binding of human immunodeficiency virus type 1 to the C3b/C4b receptor CR1 (CD35) and red blood cells in the presence of envelope-specific antibodies and complement. National Institutes of Health AIDS Vaccine Clinical Trials Networks. J Infect Dis 1994;170:429-32.
103. Schlesinger LS, Horwitz MA. Phenolic glycolipid-1 of Mycobacterium leprae binds complement component C3 in serum and mediates phagocytosis by human monocytes. J Exp Med 1991;174:1031-8.
104. Schlesinger LS, Horwitz MA. Phagocytosis of leprosy bacilli is mediated by complement receptors CR1 and CR3 on human monocytes and complement component C3 in serum. J Clin Invest 1990;85:1304-14.
105. Tausk F, Hoffman T, Schreiber R, Gigli I. Leprosy: altered complement receptors in disseminated disease. J Invest Dermatol 1985;85:58s-61s.
106. Schlesinger LS, Bellinger-Kawahara CG, Payne NR, Horwitz MA. Phagocytosis of Mycobacterium tuberculosis is mediated by human monocyte complement receptors and complement component C3. J Immunol 1990;144:2771-80.
107. Hirsch CS, Ellner JJ, Russell DG, Rich EA. Complement receptor-mediated uptake and tumor necrosis factor-alpha-mediated growth inhibition of Mycobacterium tuberculosis by human alveolar macrophages. J Immunol 1994;152:743-53.
108. Payne NR, Horwitz MA. Phagocytosis of Legionella pneumophila is mediated by human monocyte complement receptors. J Exp Med 1987;166:1377-89.
109. Robledo S, Wozencraft A, Valencia AZ, Saravia N. Human monocyte infection by Leishmania (Viannia) panamensis. Role of complement receptors and correlation of susceptibility in vitro with clinical phenotype. J Immunol 1994;152:1265-76.
110. Daniels G. The Lutheran blood group system: monoclonal antibodies, biochemistry and the effect of In(Lu). In: Pierce SR, Macpherson CR, eds. Blood group systems: Duffy, Kidd and Lutheran. Arlington: American Association of Blood Banks, 1988:119-47.
111. Telen MJ. Erythrocyte blood group antigens: not so simple after all (editorial; comment). Blood 1995;85:299-306.
112. Farley MM, Stephens DS, Kaplan SL, Mason EO Jr. Pilus- and non-pilus-mediated interactions of Haemophilus influenzae type b with human erythrocytes and human nasopharyngeal mucosa. J Infect Dis 1990;161:274-80.
113. Van Ham SM, van Alphen L, Mooi FR. Fimbria-mediated adherence and hemagglutination of Haemophilus influenzae. J Infect Dis 1992;165:897-9.
114. Van Alphen L, Poole J, Overbeeke M. The Anton blood group antigen is the erythrocyte receptor for Haemophilus influenzae. FEMS Microbiol Lett 1986;37:69-71.
115. Gilsdorf JR, Judd WJ, Cinat M. Relationship of Haemophilus influenzae type b pilus structure and adherence to human erythrocytes. Infect Immun 1989;57:3259-60.
116. Van Alphen L, Poole J, Geelen L, Zanen HC. The erythrocyte and epithelial cell receptors for Haemophilus influenzae are expressed independently. Infect Immun 1987;55:2355-8.
117. Poole J, Levene C, van Alphen L, et al. Serological and microbiological studies in a family showing inheritance of AnWj antigen (abstract). Transfusion 1989;29S:34.
118. Van Alphen L, Geelen-van den Broek L, Blass L, et al. Blocking of fimbria-mediated adherence of Haemophilus influenzae by sialyl gangliosides. Infect Immun 1991;59:4473-7.
119. b blood group antigens are located on aglycoprotein of 80,000 MW (the CDw44 glycoprotein) whose expression is influenced by the In(Lu) gene. Immunology 1988;64:37-43.
120. Telen MJ. The Lutheran antigens and proteins affected by Lutheran regulatory genes. In: Agre P, Cartron JP, eds. Protein blood group antigens of the human red cell: structure, function, and clinical significance. Baltimore: Johns Hopkins Univ Press, 1992:70-87.
121. Shepley MP, Racaniello VR. A monoclonal antibody that blocks poliovirus attachment recognizes the lymphocyte homing receptor CD44. J Virol 1994;68:1301-8.
122. St. Gerne JW 3d, Falkow S, Barenkamp SJ. High-molecular-weight proteins of nontypeable Haemophilus influenzae mediate attachment to human epithelial cells. Proc Natl Acad Sci U S A 1993;90:2875-9
123. Barenkamp SJ, Leininger E. Cloning, expression, and DNA sequence analysis of genes encoding nontypeable Haemophilus influenzae high-molecular-weight surface-exposed proteins related to filamentous hemagglutinin of Bordetella pertussis. Infect Immun 1982;60:1302-13.
124. Relman D, Tuomanen E, Falkow S, et al. Recognition of bacterial adhesin by an integrin: macrophage CR3 (αM, β2, CD11b/ CD18) binds filamentous hemagglutinin of Bordetella perrussis. Cell 1990;61:1375-82.
125. Tuomanen E, Towbin H, Rosenfelder G, et al. Receptor analogs and monoclonal antibodies that inhabit adherence of Bordetella pertussis to human ciliated respiratory epithelial cells. J Exp Med 1988;168:267-77.
126. Menozzi FD, Gantiez C, Locht C. Interaction of the Bordetella pertussis filamentous hemagglutinin with heparin. FEMS Microbiol Lett 1991;62:59-64.